Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179510 | 0.81 | LMNA (0.83) | HPGDKDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL11301261 | 0.77 | PKM (0.64) | PKMHPGDKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31313264 | 0.76 | PKM (0.67) | PKMHPGDLMNAALDH1A1MAPK1 | |
| SCHEMBL5338096 | 0.76 | PKM (0.77) | PKMHPGDLMNAALDH1A1MAPT | |
| SCHEMBL6787010 | 0.76 | LMNA (0.76) | PKMHPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1038950 | 0.76 | ALDH1A1 (0.70) | PKMHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13435824 | 0.76 | PKM (0.65) | PKMHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14184696 | 0.75 | HPGD (0.60) | PKMHPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL14641630 | 0.75 | HPGD (0.69) | PKMHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5335876 | 0.74 | PKM (0.70) | PKMHPGDLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291345-B1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6924276-B2 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | SORENSON RODERICK JOSEPH (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP3, MMP9 | PKM 3174/4885HPGD 187/4885KDM4E 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.